Patents by Inventor Wei-Hsien Ho
Wei-Hsien Ho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076362Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 1, 2023Publication date: March 7, 2024Inventors: Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL
-
Patent number: 11667699Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: July 30, 2020Date of Patent: June 6, 2023Assignee: Alector LLCInventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
-
Publication number: 20220289844Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: March 29, 2022Publication date: September 15, 2022Applicant: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Publication number: 20220249657Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: ApplicationFiled: April 20, 2022Publication date: August 11, 2022Applicant: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 11338035Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: GrantFiled: April 13, 2020Date of Patent: May 24, 2022Assignee: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Patent number: 11319373Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: May 24, 2019Date of Patent: May 3, 2022Assignee: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Publication number: 20210317208Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 30, 2019Publication date: October 14, 2021Applicant: Alector LLCInventors: Patricia CULP, Helen LAM, Wei-Hsien HO, Leonard G. PRESTA, Arnon ROSENTHAL
-
Patent number: 11091544Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: September 7, 2018Date of Patent: August 17, 2021Assignee: Rinat Neuroscience Corp.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Publication number: 20210246204Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: June 7, 2019Publication date: August 12, 2021Applicant: Alector LLCInventors: Patricia CULP, Seung-Joo LEE, Helen LAM, Wei-Hsien HO, Arnon ROSENTHAL
-
Publication number: 20210079074Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: July 30, 2020Publication date: March 18, 2021Inventors: Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL
-
Patent number: 10927178Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: August 8, 2019Date of Patent: February 23, 2021Assignee: PFIZER INC.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Publication number: 20200368349Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.Type: ApplicationFiled: April 13, 2020Publication date: November 26, 2020Applicant: RINAT NEUROSCIENCE CORP.Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
-
Publication number: 20200102394Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: ApplicationFiled: August 8, 2019Publication date: April 2, 2020Applicant: PFIZER INC.Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Wei-Hsien HO
-
Publication number: 20190359707Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 24, 2019Publication date: November 28, 2019Applicant: Alector LLCInventors: Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
-
Patent number: 10421815Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: October 22, 2018Date of Patent: September 24, 2019Assignee: Pfizer Inc.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Publication number: 20190002559Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: ApplicationFiled: September 7, 2018Publication date: January 3, 2019Applicant: RINAT NEUROSCIENCE CORP.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 10144781Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: May 31, 2017Date of Patent: December 4, 2018Assignee: Pfizer Inc.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Patent number: 10100114Abstract: The present invention provides antibodies that specifically bind to trophoblast cell-surface antigen-2 (Trop-2). The invention further provides antibody conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and Trop-2 antibody conjugates for the treatment of a condition associated with Trop-2 expression (e.g., cancer), such as colon, esophageal, gastric, head and neck, lung, ovarian, or pancreatic cancer.Type: GrantFiled: May 20, 2016Date of Patent: October 16, 2018Assignee: RINAT NEUROSCIENCE CORP.Inventors: Shu-Hui Liu, Wei-Hsien Ho, Pavel Strop, Magdalena Grazyna Dorywalska, Arvind Rajpal, David Louis Shelton, Thomas-Toan Tran
-
Patent number: 9708405Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.Type: GrantFiled: August 1, 2014Date of Patent: July 18, 2017Assignee: PFIZER INC.Inventors: Shu-Hui Liu, Flavia Mercer Pernasetti, Wei-Hsien Ho
-
Patent number: 9527926Abstract: The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and other heterodimeric proteins comprising immunoglobulin-like hinge sequences. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided.Type: GrantFiled: May 13, 2011Date of Patent: December 27, 2016Assignee: RINAT NEUROSCIENCE CORP.Inventors: Wei-Hsien Ho, Jaume Pons, Arvind Rajpal, Pavel Strop